UK Markets closed

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.25000.0000 (0.00%)
At close: 03:58PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.53
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 329.8500
52-week low 31.3200
50-day moving average 33.0120
200-day moving average 34.7702

Share statistics

Avg vol (3-month) 385
Avg vol (10-day) 3N/A
Shares outstanding 589.78M
Implied shares outstanding 6N/A
Float 821.47M
% held by insiders 156.74%
% held by institutions 127.76%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:50
Last split date 329 Apr 2013

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin -244.65%
Operating margin (ttm)-294.68%

Management effectiveness

Return on assets (ttm)-31.88%
Return on equity (ttm)-411.95%

Income statement

Revenue (ttm)15.94M
Revenue per share (ttm)0.18
Quarterly revenue growth (yoy)34.90%
Gross profit (ttm)4.96M
EBITDA -46.73M
Net income avi to common (ttm)-38.98M
Diluted EPS (ttm)-0.5500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)51.56M
Total cash per share (mrq)0.57
Total debt (mrq)52k
Total debt/equity (mrq)N/A
Current ratio (mrq)3.76
Book value per share (mrq)0.11

Cash flow statement

Operating cash flow (ttm)-29.78M
Levered free cash flow (ttm)-26.21M